HAYWARD, Calif., Sept. 9 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Kenneth Luskey, M.D. to the newly created position of Vice President, Clinical Research reporting to K. Alice Leung, the Company's CEO. In his new role, Dr. Luskey will lead the clinical development of Intarcia's proprietary drug development programs including Omega DUROS(R) therapy for hepatitis C and ITCA 650 for the treatment of type 2 diabetes.
Dr. Luskey has extensive experience in endocrinology and metabolism
research, as well as in drug development. He spent more than 13 years in
academic medicine prior to holding leadership positions with several
biopharmaceutical companies where he directed the development of new
therapies for the treatment of diabetes. Dr. Luskey began his career at the
National Institutes of Health before completing a fellowship and receiving
a faculty appointment at the University of Texas Southwestern Medical
School. While in Dallas, he worked extensively with Drs. Joseph L.
Goldstein and Michael Brown, winners of the Nobel Prize in Medicine in 1985
for their work on cholesterol metabolism. In 1991, Dr. Luskey joined Scios,
Inc. (now a member of the Johnson & Johnson family of companies) where he
led research efforts to develop new treatments for diabetes and obesity.
Subsequently, Dr. Luskey joined Metabolex, Inc. where he led research and
drug development programs focused on diabetes and impaired glucose
tolerance as Vice President, Clinical Development. Dr. Luskey also was head
of experimental medicine for Tularik Inc. (subsequently acquired by Amgen
Inc.), and was most recently head of preclinical and translational medicine
for Nuvelo, Inc. Dr. Luskey received his medical education at the
University of Texas Southwestern Medical School in Dallas. He trained in
|SOURCE Intarcia Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved